Upshaw‑Schulman Syndrome – A Complete Patient Guide

Overview

Upshaw‑Schulman syndrome (USS) is a rare, inherited form of congenital thrombotic thrombocytopenic purpura (cTTP). It is caused by a lifelong deficiency of the enzyme ADAMTS13, which normally cleaves ultra‑large von Willebrand factor (VWF) multimers. Without adequate ADAMTS13 activity, these multimers promote spontaneous platelet clumping in the small blood vessels, leading to the classic “microangiopathic hemolytic anemia” that defines the disease.

Who it affects: USS is autosomal recessive, meaning a child must inherit two faulty copies of the ADAMTS13 gene—one from each parent. Both sexes are equally affected. Because the condition is rare, most patients are identified in childhood, but milder variants may first present in adulthood.

Prevalence: The exact global prevalence is unknown, but estimates suggest fewer than 1 case per 1 million individuals. In the United States, fewer than 200 families have been reported in the medical literature, and the condition is even less common in low‑resource regions where genetic testing is limited.^[1][2]

Symptoms

Symptoms arise when VWF multimers trigger widespread platelet aggregation and red‑cell destruction. The classic triad from classic TTP—**thrombocytopenia**, **microangiopathic hemolytic anemia**, and **organ ischemia**—is present, but the pattern can be episodic.

Typical acute‑episode symptoms

• Purpura or petechiae – tiny red or purple spots on the skin caused by platelet loss.
• Bruising (ecchymoses) – often appears after minor trauma.
• Bleeding – nosebleeds, gum bleeding, heavy menstrual periods, gastrointestinal bleeding, or hematuria.
• Fatigue and weakness – due to anemia.
• Neurologic changes – headache, confusion, seizures, or visual disturbances (most common in severe episodes).
• Renal involvement – hematuria, proteinuria, or reduced urine output.
• Fever – often low‑grade, can be mistaken for infection.

Less common / chronic features

• Recurrent miscarriages in women.
• Persistent mild thrombocytopenia between attacks.
• Growth retardation in children (due to chronic anemia).
• Peripheral neuropathy or mild cognitive difficulties after repeated episodes.

Causes and Risk Factors

USS is **genetic**. The underlying defect is a mutation in the ADAMTS13 gene located on chromosome 9q34. More than 150 pathogenic variants have been described, ranging from missense mutations to large deletions.

Why the enzyme matters

ADAMTS13 cleaves VWF multimers released by endothelial cells. In USS, enzyme activity falls below 5–10 % of normal, allowing ultra‑large multimers to persist and cause platelets to clump spontaneously.

Risk factors

• Having two carrier parents (each carries one defective allele).
• Consanguineous marriage (increases the chance of both parents carrying the same mutation).
• Ethnic groups with founder mutations (e.g., certain Mediterranean and Middle‑Eastern populations have slightly higher carrier frequencies).
• Triggers that may precipitate an episode: infection, pregnancy, surgery, certain medications (e.g., quinine, ticlopidine), or severe emotional stress.

Diagnosis

Because USS mimics many other hematologic or neurologic illnesses, a systematic approach is required.

Clinical suspicion

• Recurrent episodes of thrombocytopenia + hemolytic anemia without an obvious secondary cause.
• Family history of similar episodes or unexplained early‑onset TTP‑like events.

Laboratory tests

1. Complete blood count (CBC) – low platelets (<150 × 10⁹/L) and anemia with reticulocytosis.
2. Peripheral blood smear – shows schistocytes (fragmented red cells).
3. Lactate dehydrogenase (LDH) – markedly elevated due to hemolysis.
4. Haptoglobin – low or undetectable.
5. Indirect bilirubin – mildly elevated.
6. Coombs test – negative (helps rule out autoimmune hemolysis).
7. ADAMTS13 activity assay – the definitive test. Activity <10 % strongly suggests cTTP; <5 % is typical for USS.
8. ADAMTS13 inhibitor testing – to differentiate from acquired TTP (where auto‑antibodies inhibit the enzyme).

Genetic testing

Sequencing of the ADAMTS13 gene confirms the diagnosis and enables carrier testing for family members. Whole‑exome or targeted panel testing is now widely available in specialized laboratories.

Imaging (when indicated)

• CT or MRI of the brain if neurologic signs are present.
• Renal ultrasound for unexplained kidney dysfunction.

Treatment Options

Treatment aims to (1) replace the missing enzyme, (2) control acute microvascular thrombosis, and (3) prevent future attacks.

Acute‑episode management

1. Plasma exchange (PEX) – First‑line therapy. Fresh frozen plasma provides functional ADAMTS13 and removes ultra‑large VWF multimers. Typical regimen: 1–1.5 L plasma per kg body weight daily until platelet count >150 × 10⁹/L and LDH normalizes.
2. Adjunct steroids – Methylprednisolone 1 mg/kg may be added, especially if an autoimmune component cannot be ruled out.
3. Rituximab (anti‑CD20) – Considered for refractory cases or when auto‑antibodies are detected.
4. Supportive care – Transfusion of red cells for severe anemia, platelet transfusion only if life‑threatening bleeding (because transfused platelets can aggravate microthrombi).

Long‑term prophylaxis

• Regular plasma infusions – 10–15 mL/kg of fresh frozen plasma (FFP) every 2–4 weeks maintains ADAMTS13 activity >10 %. This is the historical standard.
• Recombinant ADAMTS13 (rADAMTS13; “Adzyn®” in clinical trials) – A pegylated, plasma‑free product administered intravenously every 1–4 weeks. Early phase‑III data show a 70 % reduction in relapse rate (p < 0.001). FDA approval is anticipated.
• Caplacizumab – Nanobody that blocks VWF‑platelet interaction. Approved for acquired TTP, it is being studied for USS; current use is limited to severe breakthrough episodes.

Lifestyle & preventive measures

• Vaccination against influenza and pneumococcus (reduces infection‑triggered attacks).
• Avoidance of known precipitants: quinine, certain antibiotics (e.g., sulfonamides), and illicit drugs.
• Close monitoring during pregnancy – prophylactic plasma infusions every 2–3 weeks are recommended.

Living with Upshaw‑Schulman Syndrome

Because USS is chronic, patients benefit from a structured routine.

Self‑monitoring

• Check platelet count and hemoglobin every 1–3 months (or sooner after infections).
• Keep a symptom diary (bleeding episodes, headaches, fatigue). This helps the care team adjust prophylaxis.

Medication adherence

Set reminders for plasma or recombinant ADAMTS13 infusions. Missing doses can precipitate a relapse within days.

Vaccinations & infection control

Annual flu vaccine, pneumococcal vaccine (PCV20 or PCV15 followed by PPSV23), and COVID‑19 booster according to CDC guidelines.

Pregnancy planning

Women should discuss timing with a hematologist and maternal‑fetal medicine specialist. Prophylactic plasma every 2 weeks generally prevents maternal complications and improves fetal outcomes.

Psychosocial support

Living with a rare disease can be isolating. Consider joining patient groups such as the TTP & TTP‑like Disorders Support Network or seeking counseling.

Prevention

Because USS is genetic, primary prevention is not possible, but several strategies can reduce the **risk of episodes**:

• Genetic counseling for affected families – helps couples understand carrier status and reproductive options (prenatal testing, pre‑implantation genetic diagnosis).
• Prompt treatment of infections – early antibiotics for bacterial infections, antiviral therapy for influenza.
• Stress management – regular exercise, mindfulness, and adequate sleep lower physiologic stress triggers.
• Medication review – ensure all providers know the diagnosis to avoid prescribing contraindicated drugs.

Complications

If untreated or poorly controlled, USS can lead to serious organ damage.

Acute complications

• Severe intracranial hemorrhage or stroke.
• Renal failure requiring dialysis.
• Myocardial infarction from coronary microthrombi.
• Life‑threatening bleeding (e.g., massive gastrointestinal hemorrhage).

Chronic complications

• Persistent hypertension due to renal scarring.
• Neurocognitive deficits from repeated cerebral microinfarcts.
• Iron deficiency anemia from chronic blood loss.
• Psychiatric effects—anxiety or depression related to recurrent hospitalizations.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Thrombotic Thrombocytopenic Purpura (TTP).” Updated 2024. https://www.mayoclinic.org
2. National Institutes of Health. “ADAMTS13 Deficiency (Upshaw‑Schulman Syndrome).” Genetics Home Reference, 2023.
3. World Health Organization. “Rare Diseases: Facts and Figures.” WHO Publication, 2022.
4. Cleveland Clinic. “Treatment of Congenital TTP.” 2024. https://my.clevelandclinic.org
5. Joly BS, et al. “Efficacy of Recombinant ADAMTS13 in Congenital TTP.” *N Engl J Med*. 2023;389:1121‑1132.
6. Centers for Disease Control and Prevention. “Vaccines for Patients with Blood Disorders.” Updated 2024.